Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis
Cortesi P, Mantovani L, Ciaccio A, Rota M, Mazzarelli C, Cesana G, Strazzabosco M, Belli L. Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. American Journal Of Transplantation 2015, 15: 1817-1826. PMID: 26086300, PMCID: PMC4946849, DOI: 10.1111/ajt.13320.Peer-Reviewed Original ResearchRecipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort
Belli LS, Romagnoli R, Nardi A, Marianelli T, Donato F, Corradini SG, Iemmolo RM, Morelli C, Pasulo L, Rendina M, De Martin E, Ponziani FR, Volpes R, Strazzabosco M, Angelico M, Investigators L. Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. Digestive And Liver Disease 2015, 47: 689-694. PMID: 26055490, DOI: 10.1016/j.dld.2015.04.006.Peer-Reviewed Original ResearchConceptsRecipient female genderGraft lossFemale genderLiver transplantationRisk factorsEnd-stage liver disease (MELD) scoreFive-year graft survivalStage liver disease scoreOutcome of HCVSevere HCV recurrenceChronic hepatitis CHCV-positive patientsLiver Disease scoreHepatitis C virusHCV recurrenceGraft outcomeGraft survivalHepatitis CPortal thrombosisTransplant recipientsLiver graftsIndependent determinantsRetrospective studyC virusMatch cohort